Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk today announced the presentation of 13 abstracts at the upcoming 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), which will take place from 7 to 10 ...

In a closed-door meeting at Novo's Denmark headquarters about two months ago, the India team raised concerns that the company ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

When leaders at Novo Nordisk Canada Inc. (NNCI) wanted to focus on diversity, equity, inclusion and belonging efforts for ...

Yet at the annual meeting of the Menopause Society earlier this fall, researchers presented new evidence that hormone therapy ...

Catalent (CTLT) shares rise 1% as Novo Holdings explores contract extensions with concerned drugmakers post $16.5 billion ...

Defiance ETFs today launched NVOX, the world's first single-stock leveraged ETF for the pharmaceutical stock Novo Nordisk ...

Novo Nordisk (NYSE: NVO ), the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. However, the Danish pharmaceutical began because of more ...

Novo Nordisk’s team in India has been pushing the Danish drugmaker’s global leadership for an earlier launch of its popular weight-loss drug Wegovy over ...